Moleculin Biotech (NASDAQ: MBRX) secures CIPO intent to grant Annamycin patent

Rhea-AI Filing Summary

Moleculin Biotech, Inc. filed a current report describing new intellectual property progress for its drug candidate Annamycin. The company announced that the Canadian Intellectual Property Office has issued a notice of intent to grant Patent Application No. 3,142,510, titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from this application is expected to be issued in the coming months, which would strengthen Moleculin’s patent protection for this formulation in Canada.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001659617 0001659617 2025-09-25 2025-09-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 25, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01 Regulation FD Disclosure

On September 25, 2025, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of intent to grant for Patent Application No. 3,142,510 titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from the application is expected to be issued in the coming months.

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated September 25, 2025
104	Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date:	September 25, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster

FAQ

What did Moleculin Biotech (MBRX) report in this 8-K filing?

Moleculin Biotech reported that the Canadian Intellectual Property Office has issued a notice of intent to grant Patent Application No. 3,142,510 titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.”

Which patent application for Moleculin Biotech is moving toward grant in Canada?

The notice of intent to grant relates to Patent Application No. 3,142,510, titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.”

What stage is the Canadian patent for Moleculin Biotech’s Annamycin formulation?

The Canadian Intellectual Property Office has issued a notice of intent to grant the patent, and a patent from this application is expected to be issued in the coming months.

How did Moleculin Biotech communicate this patent development to investors?

The company issued a press release on September 25, 2025, which is attached as Exhibit 99.1 to the report and incorporated by reference.

Does the 8-K state that the information in Item 7.01 is filed or furnished?

The information in Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Securities Exchange Act of 1934 or the Securities Act of 1933 unless specifically identified as such.

What exchange is Moleculin Biotech (MBRX) listed on according to the filing?

The filing states that Moleculin Biotech’s common stock, par value $0.001 per share, trades on The NASDAQ Stock Market LLC under the symbol MBRX.